Bristol-Myers Squibb CoBMY
Price$61.46Intrinsic value$77.5826% above price

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value $77.58median of 5 methods · middle span $57-$79based on filings through 30 Jun 2026
Market Price $61.46Price as of 1 Oct 2026
Margin of Safety +26.2%as of 1 Oct 2026

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: 3.0% (near-term consensus, capped) · years 2–5: -4.3%/yr (balance of the path).-2.9% per year
Years 6–10: glide to demonstrated growth
Per-year rates
Yr 6-2.8%Yr 7-1.4%Yr 80.1%Yr 91.5%Yr 103.0%
-4.3% → 3.0%
Years 11–20: glide to long-run rate
Per-year rates
Yr 113.0%Yr 123.0%Yr 133.0%Yr 143.0%Yr 153.0%Yr 163.0%Yr 173.0%Yr 183.0%Yr 193.0%Yr 203.0%
3.0% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Historical EPS growth (multi-year median)median of 2 windows (6/7y) (limited history)5.8%
Discount rate (cost of equity) 7.1%
Volatility vs market (adjusted beta)0.49

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions Sandbox Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetBristol-Myers Squibb CoBMYHealth Care
Valuation
P/E13.5×
P/S2.6×
P/B5.8×
EV / Revenue3.3×
EV / EBITDA—
Profitability
Gross margin—
Operating margin24.2%
Net margin18.9%
FCF margin23.3%
Returns
ROE41.6%
ROA10.6%
ROIC16.4%
Growth
Revenue growth (YoY)1.8%
5-yr fwd EPS growth-2.9%
Financial strength
Debt / Equity1.92×
Current ratio1.53×
Altman Z-Score2.6
Interest coverage—
Dividend yield3.0%

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.